8:21AM Compugen announces discovery of two novel immune checkpoint targets for cancer immunotherapy (CGEN) 3.72 : Co announced the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy. These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment.
By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer. In recent in vitro studies, both of these immune checkpoint molecules have shown distinct activity inhibiting two key subtypes of immune cells, Natural Killer (NK) cells and T cells. These key immune cell subtypes act to recognize and kill tumor cells and have critical roles in the response of the immune system to tumor development.
News 
Market Data 
Discover 
